RecruitingRecruiting
ALTO-100 in Bipolar Disorder With Depression (BD-D)
NCT06656416 · Alto Neuroscience
In plain English
Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.
Official title
A Randomized, Double-Blind, Placebo-Controlled Study Followed by Open-Label Treatment of ALTO-100 in Adults With Bipolar Disorder Currently Experiencing a Major Depressive Episode
About this study
The purpose of this study is to assess antidepressant efficacy differences between ALTO-100 and placebo during the Double-Blind period in patients with bipolar disorder I or II with current major depressive episode, when used adjunctively to a mood stabilizer and/or atypical antipsychotic, related to patient characteristics. Additionally, safety, tolerability, and efficacy will be assessed in a subsequent open label treatment period.
Eligibility criteria
Inclusion Criteria:
* Have a diagnosis of BD-I or BD-II as well as BD-D
* At baseline, taking a mood stabilizer, lithium (LI) or lamotrigine (LMG) or valproic acid (VPA, any form) or combination of Li + LMG or Li + VPA and/or taking an approved atypical antipsychotic medication (olanzapine, quetiapine, lurasidone, risperidone, ziprasidone, cariprazine, aripiprazole, lumateperone, asenapine, Iloperidone and Milsaperidone) for at least 6 weeks with no dose modifications in the past 2 weeks
* Willing to comply with all study assessments and procedures
* Must not be pregnant or breastfeeding at time of enrollment or throughout study
Exclusion Criteria:
* Evidence of unstable medical condition
* Concurrent use of any prohibited medications or substance use disorder
* Diagnosed psychotic disorder (other than mania or depression)
* Current moderate or severe substance use disorder
* Has a history of hypersensitivity or allergic reaction to ALTO-100 or any of its components/excipients
* Concurrent or recent participation in another clinical trial for mental illness involving an investigational product or device
Study design
Enrollment target: 200 participants
Allocation: randomized
Masking: quadruple
Age groups: adult, older_adult
Timeline
Starts: 2024-10-02
Estimated completion: 2027-10
Last updated: 2026-10-13
Interventions
Drug: ALTO-100Drug: Placebo
Primary outcomes
- • To assess efficacy of ALTO-100 versus placebo on depression symptoms in bipolar disorder in a pre-defined subgroup of participants as measured by the mean change from Day 1 to Week 6 on the Montgomery-Åsberg Depression Rating Scale (MADRS) total score (Change assessed from Day 1 to Week 6)
Sponsor
Alto Neuroscience · industry
Contacts & investigators
ContactAlto Neuroscience · contact · clinical@altoneuroscience.com · 650-200-0412
All locations (68)
Site 6074Withdrawn
Birmingham, Alabama, United States
Site 6036Withdrawn
Chandler, Arizona, United States
Site 6000Recruiting
Phoenix, Arizona, United States
Site 6087Withdrawn
Yuma, Arizona, United States
6039Withdrawn
Fayetteville, Arkansas, United States
6070Terminated
Little Rock, Arkansas, United States
Site 6133Recruiting
Little Rock, Arkansas, United States
Site 6153Recruiting
Chino, California, United States
Site 6081Withdrawn
Imperial, California, United States
6069Recruiting
Los Angeles, California, United States
Site 6016Recruiting
Mather, California, United States
Site 6082Terminated
Oceanside, California, United States
Site 6102Withdrawn
Riverside, California, United States
Site 6111Recruiting
Sacramento, California, United States
Site 6120Recruiting
San Jose, California, United States
Site 6112Recruiting
Colorado Springs, Colorado, United States
Site 6174Recruiting
Jacksonville, Florida, United States
Site 6067Withdrawn
Lauderhill, Florida, United States
Site 6123Recruiting
Pinellas Park, Florida, United States
Site 6015Recruiting
Tampa, Florida, United States
Site 6193Not Yet Recruiting
Atlanta, Georgia, United States
Site 6068Withdrawn
Atlanta, Georgia, United States
Site 6064Recruiting
Peachtree Corners, Georgia, United States
Site 6113Recruiting
Chicago, Illinois, United States
Site 6132Recruiting
Carmel, Indiana, United States
Site 6101Terminated
West Lafayette, Indiana, United States
Site 6151Withdrawn
Baltimore, Maryland, United States
Site 6076Recruiting
Bel Air, Maryland, United States
Site 6062Recruiting
Gaithersburg, Maryland, United States
Site 6182Recruiting
Towson, Maryland, United States
Site 6188Recruiting
Worcester, Massachusetts, United States
Site 6184Recruiting
Ann Arbor, Michigan, United States
Site 6155Recruiting
Ann Arbor, Michigan, United States
Site 6178Recruiting
Grand Rapids, Michigan, United States
Site 6122Recruiting
Flowood, Mississippi, United States
Site 6142Withdrawn
Lincoln, Nebraska, United States
Site 6144Recruiting
Las Vegas, Nevada, United States
Site 6104Recruiting
Las Vegas, Nevada, United States
Site 6066Recruiting
Toms River, New Jersey, United States
Site 6014Recruiting
Albuquerque, New Mexico, United States
Site 6078Withdrawn
Albuquerque, New Mexico, United States
Site 6170Recruiting
Amherst, New York, United States
Site 6137Recruiting
New York, New York, United States
Site 6127Recruiting
Cary, North Carolina, United States
Site 6187Recruiting
Rose Hill, North Carolina, United States
Site 6029Recruiting
Cincinnati, Ohio, United States
6065Terminated
North Canton, Ohio, United States
Site 6075Recruiting
Westlake, Ohio, United States
Site 6116Recruiting
Austin, Texas, United States
Site 6105Recruiting
Beaumont, Texas, United States
Site 6176Recruiting
Dallas, Texas, United States
Site 6107Recruiting
Dallas, Texas, United States
Site 6175Recruiting
Houston, Texas, United States
Site 6072Withdrawn
Houston, Texas, United States
Site 6053Recruiting
Plano, Texas, United States
Site 6121Withdrawn
Draper, Utah, United States
Site 6177Recruiting
Fairfax, Virginia, United States
Site 6128Terminated
Bellevue, Washington, United States
Site 6409Recruiting
Derby, United Kingdom
Site 6403Recruiting
Edinburgh, United Kingdom
Site 6401Recruiting
Glasgow, United Kingdom
Site 6402Recruiting
Liverpool, United Kingdom
Site 6408Recruiting
London, United Kingdom
Site 6407Recruiting
London, United Kingdom
Site 6400Recruiting
Newcastle upon Tyne, United Kingdom
Site 6404Recruiting
Oxford, United Kingdom
Site 6406Recruiting
Southampton, United Kingdom
Site 6405Recruiting
York, United Kingdom